Table 2.
Target | Agent | Manufacturer | Study phase |
---|---|---|---|
BTK | Ibrutinib (PCI-32765) | Pharmacyclics/Janssen | 3 |
CC-292 (AVL-292) | Celgene | 1b/2 | |
GDC-0834 | Genentech | 1 | |
ACP-196 | Acerta | 1 | |
ONO-WG-307 | Ono | 1 | |
PI3Kδ | Idelalisib (GS-1101, CAL-101) | Gilead Sciences | 3 |
GS-9820 | Gilead Sciences | 2 | |
AMG-319 | Amgen | 1 | |
TGR-1202 | TG Therapeutics | 1 | |
PI3Kδ/γ | IPI-145 | Infinity | 3 |
Syk | GS-9973 | Gilead Sciences | 2 |